Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
3.90
Dollar change
+0.03
Percentage change
0.78
%
Index- P/E- EPS (ttm)-2.16 Insider Own9.93% Shs Outstand52.35M Perf Week0.26%
Market Cap204.17M Forward P/E30.00 EPS next Y0.13 Insider Trans0.00% Shs Float47.15M Perf Month11.43%
Income-21.39M PEG- EPS next Q-0.07 Inst Own92.13% Short Float0.18% Perf Quarter2.36%
Sales80.75M P/S2.53 EPS this Y93.25% Inst Trans0.45% Short Ratio1.04 Perf Half Y21.50%
Book/sh0.88 P/B4.42 EPS next Y343.75% ROA-20.53% Short Interest0.09M Perf Year110.81%
Cash/sh0.23 P/C16.89 EPS next 5Y- ROE-158.76% 52W Range1.50 - 4.38 Perf YTD-9.72%
Dividend Est.- P/FCF- EPS past 5Y21.42% ROI-18.97% 52W High-10.96% Beta1.18
Dividend TTM- Quick Ratio2.31 Sales past 5Y13.40% Gross Margin75.75% 52W Low160.00% ATR (14)0.24
Dividend Ex-Date- Current Ratio2.39 EPS Y/Y TTM16.42% Oper. Margin-1.82% RSI (14)52.06 Volatility5.66% 6.26%
Employees159 Debt/Eq1.46 Sales Y/Y TTM49.19% Profit Margin-26.49% Recom1.00 Target Price8.00
Option/ShortYes / Yes LT Debt/Eq1.44 EPS Q/Q87.13% Payout- Rel Volume0.50 Prev Close3.87
Sales Surprise8.11% EPS Surprise- Sales Q/Q87.51% EarningsMar 07 BMO Avg Volume82.62K Price3.90
SMA200.98% SMA503.18% SMA20013.53% Trades Volume41,822 Change0.78%
Date Action Analyst Rating Change Price Target Change
Mar-25-24Initiated Maxim Group Buy $10
Oct-30-23Upgrade Alliance Global Partners Neutral → Buy $8
May-28-19Initiated Craig Hallum Buy
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Mar-20-24 08:00AM
Mar-19-24 08:00AM
Mar-08-24 10:05AM
Mar-07-24 11:18PM
01:55PM
12:52PM Loading…
12:52PM
09:00AM
08:11AM
07:30AM
Feb-29-24 08:00AM
Feb-08-24 08:00AM
Jan-04-24 08:00AM
Jan-02-24 08:00AM
Dec-12-23 07:30AM
Nov-08-23 04:30PM
08:00AM Loading…
Oct-31-23 08:00AM
Oct-27-23 09:26AM
Oct-26-23 09:29AM
08:30AM
07:18AM
07:00AM
Oct-16-23 08:00AM
Oct-11-23 08:00AM
Oct-03-23 08:00AM
Sep-16-23 03:01AM
Sep-05-23 08:00AM
Aug-23-23 09:02AM
Aug-13-23 04:37AM
Aug-11-23 06:21AM
Aug-10-23 10:00PM
08:50AM Loading…
08:50AM
07:47AM
07:30AM
Aug-08-23 09:15AM
Aug-03-23 07:03PM
Aug-02-23 11:43AM
Jul-07-23 09:40AM
Jun-08-23 08:50AM
Jun-01-23 09:40AM
May-25-23 10:15AM
May-24-23 08:00AM
May-23-23 08:50AM
May-19-23 12:01PM
May-18-23 10:29PM
09:02AM
07:00AM
May-17-23 04:05PM
May-15-23 09:05AM
07:50AM
May-08-23 08:00AM
May-01-23 10:01AM
Apr-20-23 08:00AM
Apr-17-23 07:20AM
Apr-04-23 01:18PM
Apr-03-23 08:09AM
08:00AM
Mar-31-23 09:15AM
08:00AM
Mar-27-23 08:00AM
Mar-24-23 04:05PM
Feb-27-23 08:00AM
Feb-22-23 08:00AM
Jan-09-23 08:00AM
Dec-29-22 06:02AM
Dec-08-22 08:00AM
Nov-29-22 08:00AM
Nov-17-22 03:54PM
Nov-16-22 05:05AM
Nov-14-22 08:55AM
07:30AM
Nov-02-22 08:00AM
Nov-01-22 08:00AM
Oct-20-22 09:40AM
Oct-18-22 09:03AM
Oct-06-22 08:00AM
Sep-23-22 08:00AM
Sep-20-22 08:00AM
Sep-19-22 09:40AM
Sep-02-22 09:40AM
Aug-31-22 08:48AM
Aug-29-22 08:50AM
Aug-19-22 08:50AM
Aug-17-22 09:40AM
Aug-10-22 08:00AM
Aug-09-22 08:00AM
06:47AM
Aug-05-22 08:50AM
Aug-01-22 09:40AM
Jul-27-22 08:45AM
07:30AM
Jul-26-22 08:00AM
Jul-22-22 10:34AM
08:00AM
Jul-13-22 08:00AM
Jul-08-22 08:00AM
Jun-24-22 07:10AM
Jun-08-22 08:03AM
Jun-02-22 08:00AM
May-12-22 08:03AM
May-09-22 09:15AM
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Caligan Partners LP10% OwnerSep 14 '23Buy3.39579,0001,962,81016,835,154Sep 15 04:05 PM
Caligan Partners LP10% OwnerSep 14 '23Sale3.39579,0001,962,81016,256,154Sep 15 04:05 PM
Morgan AdamDirectorMay 17 '23Buy1.701,401,9012,383,2321,659,654May 19 05:17 PM